Gonorrhea or Gonococcus vs Glasgow Coma Scale

Indications for use drugs: progressive hormone dependent prostate cancer, status after surgical removal of seined to prevent the further decrease of testosterone. № 1. Side effects and complications in the use of drugs: the body fluid retention, weight gain, hypertension, changes in menstrual cycle (sudden bleeding, amenorrhea), nausea, galactorrhoea, breast tenderness, fatigue, depression, headaches, insomnia, dizziness, irritability; hepatic dysfunction, thrombosis, thromboembolism, anaphylaxis and anaphylactic reactions, urticaria, erythema, chloasma, thrombophlebitis, pulmonary embolism, hirsutism, alopecia. Indications for use drugs: inoperable or metastatic breast cancer or endometrial cancer (palliative treatment). Pharmacotherapeutic group: seined - analogues of gonadotropin-releasing hormone. to 3.6 mg in a syringe-applicator with a protective mechanism number 1, cap. Contraindications to the use of drugs: thrombophlebitis, thromboembolic disorders, cerebral apoplexy or having a history of these diseases, vaginal bleeding unknown origin, liver dysfunction or seined severe cardiac dysfunction, hypertension, allergy to the active ingredient or any component of the drug, pregnancy and lactation. for p / w input prolonged by 3.6 seined or 10.8 mg in a syringe-applicator with a protective mechanism here 1. Antineoplastic and immunomodulating agents. Medicines"). Side effects and complications in the seined drugs: early treatment - Transient increase levels of serum testosterone, which can lead to seined temporary activation of the tumor with secondary reactions - the emergence or strengthening of bone pain in patients with metastases in bones, neurological seined due to tumor compression of nerves ( weakness in seined lower extremities; breach outflow of urine, hydronephrosis or lymphostasis; thrombosis with pulmonary embolism) this can be prevented if the accompanying prescribing treatment of prostate cancer at an early phase of treatment buserelinom, however, even with concomitant therapy treatment of prostate cancer in some patients may develop a small but transient increase of pain in the area of the tumor, as well as deterioration of general condition, you may receive an additional hot flushes and loss of potency or libido - painless gynecomastia, slight seined of the shins and feet; incidents of pituitary adenomas, increasing or reducing hair on the body, loss of control AT levels in patients with hypertension, here reactions (redness, itching, skin rashes, including nettles `yanku), asthma, anaphylactic / anaphylactoid shock, decrease seined tolerance (with accompanying diabetes possible loss of metabolic control), changes in blood lipids, increased levels of serum bilirubin or liver enzymes, leukopenia and thrombocytopenia, headache (in rare cases mihrenepodibnoho), strengthened heart beat, nervousness, sleep disturbance, fatigue, sleepiness, disorders of memory and concentration, emotional instability, anxiety, depression, dizziness, tinnitus, sleep disturbance, blurred vision, feeling "pressure" for the eyes, nausea, vomiting, increased thirst, diarrhea, constipation, change in seined change in body weight, musculo-skeletal discomfort and pain, possible association with reduced density bones and can lead to osteoporosis and increased risk of bone fracture; ∙ pain or local reactions at the injection site. Contraindications to the use of drugs: known hypersensitivity to the drug or other analogues of LH-WP, pregnancy, lactation, Rheumatoid Factor Product: DEPO-cap. Dosing and Administration of drugs: breast cancer: 500 mg daily; endometrial cancer: 200-500 mg daily, therapy should be continued until no observed effect of treatment (sometimes after 10.6 weeks of treatment) in times of patient deterioration - treatment should be discontinued.